Figure 3
Figure 3. Effect of APECED sera on ISG expression and STAT1 phosphorylation. (A) Expression of ISGs in control monocytes incubated in 20% autologous sera with the addition of 2% APECED sera-positive (Ab+) or -negative (Ab−) for IFN-α antibodies, or with control serum (Ctrl) for 18 hours. *P < .05 between IFN-α antibody–positive APECED patients and healthy controls. (B) U937 cells were treated with 1000 U/mL IFN-α for 15 minutes or with the same concentration of IFN-α preincubated with 2%, 5%, or 10% of APECED (A1-A5) or 10% of control (C1-C3) sera, stained for intacellular pSTAT1 and measured by flow cytometry. (C) Control PBMCs were incubated with 50% of serum samples from APECED patients positive (Ab+) or negative (Ab−) for IFN-α antibodies, healthy controls (Ctrl), or SLE patients for 15 minutes and stained for intracellular pSTAT1 to test for IFN activity in the sera (left panel). Control PBMCs were incubated with 50% of serum samples from an APECED patient negative for IFN-α autoantibodies (A3), an SLE patient with IFN activity, or two healthy controls for 15 minutes with or without the addition of neutralizing anti–IFN-α antibody or isotype control antibody as indicated, and stained for intracellular pSTAT1 (right panel).

Effect of APECED sera on ISG expression and STAT1 phosphorylation. (A) Expression of ISGs in control monocytes incubated in 20% autologous sera with the addition of 2% APECED sera-positive (Ab+) or -negative (Ab) for IFN-α antibodies, or with control serum (Ctrl) for 18 hours. *P < .05 between IFN-α antibody–positive APECED patients and healthy controls. (B) U937 cells were treated with 1000 U/mL IFN-α for 15 minutes or with the same concentration of IFN-α preincubated with 2%, 5%, or 10% of APECED (A1-A5) or 10% of control (C1-C3) sera, stained for intacellular pSTAT1 and measured by flow cytometry. (C) Control PBMCs were incubated with 50% of serum samples from APECED patients positive (Ab+) or negative (Ab) for IFN-α antibodies, healthy controls (Ctrl), or SLE patients for 15 minutes and stained for intracellular pSTAT1 to test for IFN activity in the sera (left panel). Control PBMCs were incubated with 50% of serum samples from an APECED patient negative for IFN-α autoantibodies (A3), an SLE patient with IFN activity, or two healthy controls for 15 minutes with or without the addition of neutralizing anti–IFN-α antibody or isotype control antibody as indicated, and stained for intracellular pSTAT1 (right panel).

Close Modal

or Create an Account

Close Modal
Close Modal